The once weekly self-injected treatment is the first dual-binding nanobody C5 inhibitor approved for adults with AChR ...
The UCSF Health–based leukemia and lymphoma specialist outlines chemo-free DLBCL, dual-targeted CAR T-cell therapy, and MRD-guided deescalation.
In the phase 3 ECLIPSE 1 trial, 44% on elebsiran plus tobevibart met the primary end point, with no treatment stops due to serious adverse events.
Crescent Moore, PharmD, PhD, explained how health plans can evaluate menopause therapies, audit coverage, and measure outcomes beyond spending.
T-cell infusion can clear heavily pretreated myeloma in 2 weeks, highlighting the immune system’s adaptability.
The action is based on phase 3 VOLGA results, which were presented at the ESMO Congress 2026. They support a perioperative ...
Research at ObesityWeek 2026 tracks rising obesity in Medicare, productivity losses, prior authorization denials, and GLP-1 ...
Mike Sharma, MD, discusses early efficacy signals, long-term stroke risk, patient impact, and why antithrombotic treatment ...
Protein intake below 0.6 g/kg/d was linked to a higher risk of kidney failure and death, according to a Korean cohort study.
From 9.6 million US diabetic retinopathy cases to a new FDA warning on GLP-1s, here are 5 things to know about diabetic eye ...
A new tool puts this year's measles toll at nearly $83 million as global health experts weigh whether the US has lost elimination status.
The FDA approved asundexian (Sunharbo) with antiplatelet therapy to reduce recurrent stroke risk after noncardioembolic ...